UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 9, 2005
(August 8, 2005)
DOV PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 000-49730 22-3374365
(State or Other (Commission File No.) (IRS Employer
Jurisdiction of Identification No.)
Incorporation)
433 Hackensack Avenue, Hackensack, NJ 07601
-------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, including Area Code: (201) 968-0980
--------------
Not applicable
--------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240-14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240-13e-4(c))
ITEM 1.01. Entry Into a Material Definitive Agreement
On August 8, 2005, registrant announced that it and MSD Warwick
(Manufacturing) Ltd., an affiliate of Merck & Co, Inc., have amended the
exclusive license, development and commercialization agreement dated August 5,
2004, between the parties. The text of the press release issued in connection
with the announcement is filed as Exhibit 99.1 to this current report on Form
8-K.
ITEM 2.02. RESULTS OF OPERATION AND FINANCIAL CONDITION.
On August 9, 2005, registrant announced its financial results for the
quarter ended June 30, 2005. The text of the press release issued in connection
with the announcement is filed as Exhibit 99.2 to this current report on Form
8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in
this current report, including Exhibit 99.1, shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of that section unless registrant
incorporates it by reference into a filing under the Securities Act of 1933, as
amended.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits. The following exhibits are filed with this current report on Form
8-K.
Exhibit No. Title
99.1 Press Release dated August 8, 2005, of DOV Pharmaceutical, Inc.
99.2 Press Release dated August 9, 2005, of DOV Pharmaceutical, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DOV Pharmaceutical, Inc.
Date August 9, 2005 By: /s/ Leslie Hudson
------------------------------------------------
Leslie Hudson
President and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Title
99.1 Press Release dated August 8, 2005, of DOV Pharmaceutical, Inc.
99.2 Press Release dated August 9, 2005, of DOV Pharmaceutical, Inc.